Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
This article was originally published in The Pink Sheet Daily
Agency decides against requiring coverage with evidence development for off-label uses.
You may also be interested in...
Draft national coverage decision addresses current indications and hospital sites of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.
Medicare begins analysis process for CAR-T cancer therapies in response to a request from UnitedHealthcare for a national coverage policy.
The director of Medicare’s coverage group sees the ability to pay physicians for providing a placebo in clinical trials required under a ‘coverage with evidence development’ determination as a major improvement in its recent guidance for CED.